Atoltivimab
drugOn this page
Also known as Atoltivimab component of inmazeb -ebgnAtoltivimab component of regn-eb3Atoltivimab-ebgnRegn-3470REGN3470
Summary
Atoltivimab (CHEMBL4298183) is an approved antibody; indicated across 1 condition including ebola hemorrhagic fever.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298183 |
| Name | Atoltivimab |
| Type | Antibody |
| Max phase | 4 |
Also known as: Atoltivimab, Atoltivimab component of inmazeb -ebgn, Atoltivimab component of regn-eb3, Atoltivimab-ebgn, Regn-3470, REGN3470, ATOLTIVIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Ebola hemorrhagic fever | 4 | MONDO:0005737 | EFO:0007243 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: Ebola hemorrhagic fever